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Original ArticleEpigenetic Inactivation of SOX30 Is Associated
with Male Infertility and Offers a Therapy
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University, Chongqing, ChinaNon-obstructive azoospermia (NOA) is the most severe form
of male infertility. However, the etiology of NOA is largely
unknown, resulting in a lack of clinical treatments. Here, we
performed a comparative genome-wide proﬁling of DNA
methylation and identiﬁed SOX30 as the most notably hyper-
methylated gene at promoter in testicular tissues from NOA
patients. This hyper-methylation at promoter of SOX30
directly causes its silencing of expression in NOA. The reduced
levels of SOX30 expression are correlated with severity of NOA
disease. Deletion of Sox30 inmice uniquely impairs testis devel-
opment and spermatogenesis with complete absence of sperma-
tozoa in testes leading tomale infertility, but does not inﬂuence
ovary development and female fertility. The pathology and
testicular size of Sox30 null mice highly simulate those of
NOA patients. Re-expression of Sox30 in Sox30 null mice at
adult age reverses the pathological damage of testis and restores
the spermatogenesis. The re-presented spermatozoa after re-
expression of Sox30 in Sox30 null mice have the ability to start
a pregnancy. Moreover, the male offspring of Sox30 re-expres-
sion Sox30 null mice still can father children, and these male
offspring and their children can live normally more than 1
year without signiﬁcant difference of physical appearance
compared with wild-type mice. In summary, methylated inacti-
vation of SOX30 uniquely impairs spermatogenesis, probably
causing NOA disease, and re-expression of SOX30 can success-
fully restore the spermatogenesis and actual fertility. This study
advances our understanding of the pathogenesis of NOA, offer-
ing a promising therapy target for NOA disease.Received 8 April 2019; accepted 31 October 2019;
https://doi.org/10.1016/j.omtn.2019.10.038.
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Infertility is the most severe problem in reproductive health.1
Approximately half of infertility in humans is attributed to male fac-
tors, and 15% of these factors are azoospermia with complete
absence of sperm in the semen.2–4 Azoospermia is classiﬁed into72 Molecular Therapy: Nucleic Acids Vol. 19 March 2020 ª 2019 The A
This is an open access article under the CC BY-NC-ND license (http:obstructive azoospermia (OA), comprising about 40%, and non-
obstructive azoospermia (NOA), comprising about 60% of azoosper-
mic cases. OA accompanied by normal spermatogenesis in testes is
the consequence of physical blockage to the excurrent ducts and fails
to produce mature sperm.5–7 NOA, as the severest form of human
male infertility, is the consequence of abnormal spermatogenesis in
testes and fails to produce testicular sperm. Up to now, more than
80% of NOA cases remain unclear in etiology.8
Although numerous genetic testing studies have been performed,
genetic abnormalities have been detected in only 20% of NOA pa-
tients.4,9 It remains largely unknown whether epigenetic changes
are associated with NOA disease. DNA methylation is an epige-
netic modiﬁcation that plays important roles in various dis-
eases.10–14 Accumulating evidence has suggested that a normal
methylation pattern in germ cell is highly associated with male
fertility.15–18 In our present study, we performed a comparative
genome-wide proﬁle of DNA methylation and gene expression
in testicular biopsy specimens between OA and NOA patients.
SOX30 was identiﬁed as the most notably hyper-methylated gene
at promoter and a silent gene in NOA patients. SOX30 was inac-
tivated by DNA methylation at promoter rather than genetic vari-
ation in NOA. Indeed, SOX30 deﬁciency was tightly correlated
with NOA disease. The in vivo function of Sox30 was then
explored in testis development of Sox30 knockout mice. The pa-
thology and testicular volume of Sox30 null mice were compareduthor(s).
//creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. SOX30 Is Identified as a Hyper-Methylated
Gene in NOA Testicular Tissues
(A) DNA methylation levels of different gene regions in
NOA testicular tissues compared with in OA testicular
tissues. The arrow represents the hyper-methylated
region in NOA. (B) Identification of SOX30 as a pref-
erentially methylated gene on chromosome 5 (Chr5)
in NOA samples using genome-wide methylation
screening. Circos plot shows Chr5 methylation pattern
in OA and NOA samples. The chromosomal zone, GC
content, repeated sequence content, gene sequence
content, methylation level of OA, and methylation level
of NOA are presented from the outer circle to the inner
circle in the Circos figure. The arrows represent
preferential methylated sites of SOX30 gene in NOA
samples. Orange box represents SOX30 promoter.
The hyper-methylated CpG sites that are negatively
associated with SOX30 expression have been indi-
cated with arrows in red. (C) Hierarchical clustering
of differentially methylated sites of SOX30 in
other independent testicular tissue samples of NOA
and OA patients. The key color bar indicates methyl-
ation levels. NOA-S1, NOA-S2, NOA-S3, OA-S1, OA-
S2, and OA-S3 represent NOA-Sample1, NOA-Sam-
ple2, NOA-Sample3, OA-Sample1, OA-Sample2, and
OA-Sample3, respectively.
www.moleculartherapy.orgwith that of NOA patients. Moreover, the potential application of
Sox30 to cure NOA disease by restoring Sox30 expression was
evaluated. This study identiﬁed SOX30 as a key male-speciﬁc fac-
tor involved in infertility, providing a prospective target for the
treatment of human NOA disease.
RESULTS
Study Participants
The main purpose of this study is to identify novel and key methyl-
ated genes associated with germ cells or spermatogenesis in NOA dis-
ease. The OAmen who exhibit normal tissue morphology with a large
number of sperm and no signiﬁcant reduction in spermatogenic cells
in testis tissues were selected as the control tissues. Moreover, the
selected OA patients underwent testicular sperm extraction (TESE)
or microsurgical epididymal sperm aspiration (MESE) for assisted
reproduction and could father children. The composition of cell types
varies greatly in NOA patients. To eliminate other factors as much as
possible, the NOA samples with clear composition of cell types and
pathological morphology were selected. The NOA patients could be
classiﬁed into four groups according to composition of cell types:
NOA-I patients without spermatozoa, NOA-II patients without sper-
matids, NOA-III patients without spermatocytes, and NOA-SCO
(Sertoli cell-only) patients without spermatogenic cells (Figure S1).
However, the NOA-SCO patients were excluded in the present study
because we would like to identify the novel and key related genes in
NOA disease that are associated with germ cells or spermatogenesis.
Based on the above criteria, we screened 502 cases of OA and NOA inmen and selected 15 well-matched OA patients from 326 OA men
and 58 NOA patients from 176 NOA men for this study. These
selected NOA patients included 31 cases of NOA-I, 22 cases of
NOA-II, and 5 cases of NOA-III. The detailed characteristics of the
participants selected are shown in Table S2.
SOX30 Is Hyper-Methylated in Testicular Tissues of NOA
Patients
To understand the pathogenesis of human NOA disease, we analyzed
by direct bisulﬁte sequencing the globalDNAmethylation inﬁveNOA
and ﬁve OA patients’ testicular tissues selected randomly from the 15
OApatients and 58NOApatients. A total of 5,832 differentially meth-
ylated regions (DMRs; p < 0.01) were detected in NOA compared with
OA. These DMRs were mainly distributed in intergenic regions
(48.56%), intron regions (34.74%), upstream regions (promoter re-
gions, 9.23%), and downstream regions (5.74%) of genes (Figure S2A).
The 5,832DMRswere located at 2,189 genes showing a different status
of DNAmethylation in NOA compared with OA (1,391 hyper-meth-
ylated genes and 798hypo-methylated genes) (Table S3). The distribu-
tion of the hyper-methylated DMRs in NOA compared with OA was
centered in the upstream regions of genes, and the hyper-methylated
DMRs at promoter of genes preferentially existed on chromosome 3
(Chr3), chromosome 18 (Chr18), and chromosome 5 (Chr5) (Fig-
ure 1A; Figure S2B; Table S3). Among these hyper-methylated regions
at promoter of genes on Chr3, Chr18, and Chr5, SOX30 was found
to be one of the most notably hyper-methylated genes at
promoter (p = 3.23E6) (Table 1; Table S3). Moreover, 25 seriousMolecular Therapy: Nucleic Acids Vol. 19 March 2020 73
Table 1. The Hyper-Methylated Genes of Chromosome 3, Chromosome 18, and Chromosome 5 with DMRs on the Promoter Region Were Listed between
Testicular Tissues of OA and NOA Patients
DMR Location
Methylation
p Value (MWU-Test) Gene Symbol and No. Gene RegionOA NOA
Chr3 0.17033 0.59108 0.0083 CRTAP; NM_006371 promoter
Chr3 0.2225 0.7972 0.00073 C3orf84; NM_001080528 promoter
Chr3 0.0000 0.2695 0.00013 USP4; NM_003363 promoter
Chr3 0.42783 0.86725 0.0005 NICN1; NM_032316 promoter
Chr3 0.22264 0.79 0.00014 RPL29; NM_000992 promoter
Chr3 0.10645 0.57564 0.00039 DENND6A; NM_152678 promoter
Chr3 0.07791 0.29973 0.0066 LINC00960; NR_040005 promoter
Chr3 0.075 0.8352 2.20E5 ROBO1; NM_00114584 promoter
Chr3 0.22642 0.87092 6.40 E6 OR5AC2; NM_054106 promoter
Chr3 0.31021 0.76793 0.0028 TXNRD3; NM_001173513 promoter
Chr3 0.118 0.72015 3.70 E6 TPRA1; NM_001136053 promoter
Chr3 0.0000 0.4205 0.0011 RBP1; NM_002899 promoter
Chr3 0.1516 0.6282 0.0029 LOC100128164; NR_027622 promoter
Chr3 0.123 0.4503 0.0015 SKIL; NM_001145097 promoter
Chr3 0.4009 0.9353 1.10E5 HTR3E; NM_001256614 promoter
Chr3 0.3481 0.8349 0.00032 SDHAP2; NR_003265 promoter
Chr18 0.1459 0.7482 1.10E5 IMPA2; NM_014214 promoter
Chr18 0.0275 0.4705 0.0039 OSBPL1A; NM_080597 promoter
Chr18 0.1906 0.7729 1.10E5 TCEB3CL; NM_001100817 promoter
Chr18 0.1191 0.7259 1.10E5 TCEB3CL2; NM_001242907 promoter
Chr18 0.2709 0.9206 0.00049 ELAC1; NM_018696 promoter
Chr18 0.000 0.67609 3.80E6 C18orf63; NM_001174123 promoter
Chr5 0.1871 0.891 1.10E5 PDZD2; NM_178140 promoter
Chr5 0.2086 0.7136 0.0039 SDHA; NM_004168 promoter
Chr5 0 0.9022 6.70E6 MCCC2; NM_022132 promoter
Chr5 0.2142 0.8657 1.10E5 SSBP2; NM_001256732 promoter
Chr5 0.1527 0.6681 0.0015 ZCCHC10; NM_017665 promoter
Chr5 0.1865 0.4772 0.00049 CDC23; NM_004661 promoter
Chr5 0.2264 0.671 0.00027 SNORD63; NR_002913 promoter
Chr5 0.2774 0.8002 0.00073 MAT2B; NM_182796 promoter
Chr5 0.4716 0.6994 0.0014 FAM153B; NM_001265615 promoter
Chr5 0.2628 0.5196 0.0033 HNRNPAB; NM_004499 promoter
Chr5 0.4017 0.9711 3.23E6 SOX30; NM_178424 promoter
Molecular Therapy: Nucleic Acidshyper-methylated sites of CpG island were identiﬁed at the promoter
of SOX30 in NOA patients compared with OA patients (Figure 1B;
Table S4). The global DNA methylation was also analyzed using mi-
croarrays in three other independent NOA and three OA patients’
testicular tissues.19,20 In the differentially methylated genes of methyl-
ation microarray, SOX30 was also signiﬁcantly hyper-methylated at
promoter in NOA compared with OA patients (kindly analyzed by
Z.-m.L. and X. Zhuang in Xiamen University; Figure 1C). These
data demonstrate that SOX30 is a remarkably hyper-methylated
gene at promoter in testicular tissues of NOA patients.74 Molecular Therapy: Nucleic Acids Vol. 19 March 2020SOX30 Silenced by Hyper-Methylation at Promoter Is Highly
Associated with NOA
To determine the effect of methylation on gene expression, we per-
formed a transcriptome study using microarray in the same NOA
and OA patients’ testicular tissues as the methylation microarray
analyzed. Over 1,900 upregulated and 2,700 downregulated genes
were found comparing NOA with OA (fold change >2 or <1/2), and
SOX30 was identiﬁed as a prominent silenced gene in NOA by cluster
analysis of gene expression proﬁling (Figure 2A). By integration ana-
lyses of the data from methylation and expression microarrays, we
Figure 2. SOX30 Silenced by Hyper-Methylation Is
Closely Associated with NOA
(A) Hierarchical clustering of differentially expressed
genes (R2-fold) in testicular tissues of three NOA
(NOA-S1, -S2, -S3) patients as compared with that of
three OA (OA-S1, -S2, -S3) patients, and identification of
SOX30 as a preferentially silenced gene in NOA patients.
The key color bar indicates mRNA expression levels. (B)
IHC staining of SOX30 was performed in the testicular
biopsy specimens from OA and NOA patients. NOA-I,
NOA-II, and NOA-III represent the NOA patients
without spermatozoon, the NOA patients without sper-
matid, and the NOA patients without spermatocyte,
respectively. The arrows represent spermatozoa, sper-
matids, and spermatocyte. Scale bars represent 20 mm.
(C) IHC staining of SOX30 was quantified in the
testicular biopsy specimens of OA and NOA patients.
****p < 0.0001.
www.moleculartherapy.orgfound that multiple hyper-methylated CpG sites on SOX30 promoter
are negatively associated with SOX30 expression (Figures 1B, 1C, and
2A). Immunohistochemistry (IHC) staining of testicular tissues from
the OA and NOA patients conﬁrmed that SOX30 expression was
signiﬁcantly decreased in testicular tissues of NOA patients compared
with OA patients (p < 0.0001; Figures 2B and 2C). In the divided three
groups of NOA patients, NOA-I, NOA-II, and NOA-III patients, the
levels of SOX30 expression were continuously decreased fromNOA-I
patients (5.742 ± 0.9147), to NOA-II patients (3.091 ± 1.0405), to
NOA-III patients (0.4000± 0.8; p < 0.0001; Figures 2B and 2C).More-
over, Sox30 is silenced by hyper-methylation and can be restored by
de-methylation treatment with 5-aza-dc in mouse GC2 (spermato-
cyte), TM3 (Leydig cell), and TM4 (Sertoli cell) cell lines in our previ-
ous study.21 To exclude the possibility that silencing of SOX30 in NOA
is caused by genetic variations, we screenedmutations and deletions in
testicular tissues of the ﬁve NOA patients that performed global DNA
methylation using direct sequencing. DNA sequencing revealed that
there was no mutation or deletion except only a known SNP site
(rs35793864) of SOX30 in NOA patients (Table S5). These data indi-
cate that the silencing of SOX30 caused by hyper-methylation at
promoter is closely associated with NOA disease.
Sox30 Deletion Uniquely Impairs Testis Development, Causing
Infertility
Functional network analysis of gene expression proﬁling demon-
strated that SOX30-associated gene sets were involved in sexualMolecular Treproduction, male gamete generation, and
spermatogenesis processes (Figure S3). Further-
more, SOX30 expression was positively associ-
ated with testicular volume (p = 0.001) of
NOA patients (Table S6). These data suggested
a potential role for SOX30 in regulating testis
development and spermatogenesis. To explore
the biological role of Sox30 on testis develop-
ment, we generated a Sox30 null mouse model(Figures S4A and S4B). Homozygous (Sox30/) and heterozygous
(Sox30/+) mice developed normally and lived more than 17 months
without obvious differences in general physical appearance compared
with their wild-type (Sox30+/+) littermates. Sox30/ female mice
were fertile, but Sox30/ male mice were fully sterile (Figures 3A
and 3B; Table S7). Sox30/, Sox30/+, and Sox30+/+ female mice
have similar ovaries, whereas Sox30/ male mice showed signiﬁ-
cantly small testes compared with Sox30+/+ or Sox30/+ mice (Fig-
ure 3C; Figures S5 and S6A–S6D). Furthermore, the loss of Sox30/
testis weight became more severe as mice aged (Figure 3D; Fig-
ure S6E). These results demonstrate that Sox30 is essential for testis
development and male fertility.
Sox30 Deletion Impairs Spermatogenesis, Resulting in Absence
of Spermatozoa
To determine the potential causes of abnormal testis development
and male infertility, we examined the gametes in epididymides and
testes of Sox30 null mice. Sox30/ mice completely lacked sperma-
tozoa in their epididymides and exhibited disorganized testis
morphology with multi-nucleated spermatogenic cells, few sperma-
tids, and complete absence of spermatozoa in their seminiferous tu-
bules by histological examination and analyzing semen (Figure 3E;
Figures S7A and S7B). The few spermatids and complete absence of
spermatozoa in testes of Sox30/ mice were further conﬁrmed
by semithin histological section, electron-microscopy examination,
and expression analysis of spermatid markers: Tnp1 and Prm2herapy: Nucleic Acids Vol. 19 March 2020 75
Figure 3. Sox30 Is Required Specifically for Male Fertility and Testis Development
(A) The fertility was analyzed in different Sox30 genotypes of mice. +/+ represents wild-type mice (Sox30+/+), /+ represents heterozygous mice (Sox30/+),
and/ represents homozygous mice (Sox30/). (B) qRT-PCR andWB analyses of the expression of Sox30 in testes of mice with indicated genotypes. **p < 0.01. b-Actin
was used as an internal control. (C) The morphology and weight of testes (Sox30+/+: n = 15, Sox30/+: n = 19, and Sox30/: n = 14) were analyzed in Sox30+/+, Sox30/+,
and Sox30/ mice. **p < 0.01. Scale bar represents 0.5 cm. (D) The weight of testes from Sox30/ mice at different developmental stages (40, 120, and 180 days post-
partum [dpp]) were compared. **p < 0.01. (E) H&E staining of epididymis and testis sections were shown from Sox30+/+ (n = 10), Sox30/+ (n = 10), and Sox30/ (n = 10)
mice older than 5 months. The arrows in epididymis represent spermatozoa. The arrows in testes represent spermatozoa and spermatids. Scale bars represent 50 mm.
Molecular Therapy: Nucleic Acids(Figures S8A–S8C). These results reveal that deletion of Sox30 in mice
impairs spermatogenesis, exhibiting few spermatids and complete
absence of spermatozoa in testes.
The Pathology and Testicular Size of Sox30–/– Mice Simulate
Those of NOA Patients
To further determine the implication of SOX30 on NOA disease, we
compared the testicular pathology of Sox30 null mice with that of
NOA patients. No spermatozoa and few spermatids were observed
in testes of 6-month-old Sox30-deﬁcient mice, which are similar to
the phenotypes of NOA-II patients (Figure 4A; Figure S9A). No sper-
matozoa, no spermatids, and a few spermatocyte-like cells were found76 Molecular Therapy: Nucleic Acids Vol. 19 March 2020in 8-month-old Sox30-deﬁcient mice, which are very similar to the
phenotypes of NOA-III patients (Figure 4A; Figure S9A). To deter-
mine whether the loss of testicular volume of NOA patients becomes
more severe as they age, we compared the testicular volume of NOA
and OA patients at different ages. The testicular volume of the NOA-
II+III patients (highly similar to the phenotypes of Sox30-deﬁcient
mice) who are young (%30 years) was signiﬁcantly greater than
that of the NOA-II+III patients who are older (>30 years) (p =
0.0218; Figure 4B). However, no difference was found between testic-
ular volume of the young (%30 years) NOA-I patients and the older
(>30 years) NOA-I patients (p = 0.9895; Figure S9B), which is also
applicable to the OA patients (p = 0.3943; Figure S9B). In addition,
Figure 4. The Pathology and Testicular Size of
Sox30–/– Mice Simulate Those of NOA Patients
(A) H&E staining of testes from human NOA patients and
Sox30/ mice at 6-month (n = 10) or 8-month (n = 8)
developmental stage were compared. Almost only sper-
matocyte-like, spermatogonia, and Sertoli cells were
observed in 6-month-old Sox30-deficient mice. A few
spermatocyte-like and almost only spermatogonia and
Sertoli cells were found in 8-month-old Sox30-deficient
mice. Scale bars, 50 mm. (B) The testicular volume of NOA
patients at different ages was compared. The NOA-II+III
(%30) represents these NOA-II and NOA-III patients who
are less than and equal to 30 years, and the NOA-II+III
(>30) represents these NOA-II and NOA-III patients who
are greater than 30 years. (C) The testicular volume of OA
and NOA patients was compared. ****p < 0.0001.
www.moleculartherapy.orgthe testicular volume of OA patients is signiﬁcantly greater than that
of NOA patients (p < 0.0001), and the testicular volume was contin-
uously decreased from NOA-I patients, to NOA-II patients, to NOA-
III patients (p < 0.0001; Figure 4C). The data are consistent with the
results of SOX30 expression in OA andNOA patients (Figures 2B and
2C) and the testis size of Sox30/ mice (Figure 3C). These results
indicate that the testicular pathology and testicular size of Sox30-deﬁ-
cient mice highly simulated those of NOA patients.
The Infertility of Sox30 Deletion Can Be Cured by Restoration of
Sox30
We next investigated whether the male infertility of Sox30 deﬁciency
can be cured by re-expression of Sox30 in adult mice. Sox30 expres-
sion was restored in Sox30/ mice by deleting the ﬂoxed cassette
(Sox30loxp/loxp) using tamoxifen (tam) that activates the estrogen re-
ceptor (ER)-Cre (Figure S4A). These mice were sacriﬁced at 2 and
6 months after the ﬁrst tam injection. The histological data showed
a presence of spermatids and spermatozoa in some seminiferous tu-
bules of testes and visible spermatozoa in epididymides from Sox30-
loxp/loxp mice (Figure 5A). These results reveal that re-expression of
Sox30 can restore spermatogenesis in adult Sox30/mice. It is note-
worthy that the mice analyzed at 6 months seemed to have a better
restoration of spermatogenesis than those analyzed at 2 months after
tam administration (Figure 5A).
We then evaluated the ability to conceive of the re-presented sperma-
tozoa after re-expression of Sox30 in male Sox30/ mice by fertility
analyses. The data showed that the male Sox30+/+ mice injected
with tam were fertile in 100% (5/5), the male Sox30/+ mice injected
with tam were fertile in 88.9% (8/9), and the male Sox30/ mice in-
jected with solvent were fully sterile (0/8). Unexpectedly, the maleMolecular TSox30loxp/loxp mice (Sox30/ mice injected
with tam)were fertile in 42.9% (6/14) (Figure 5B),
whereas the number of descendants was
relatively small (usually two to four) in the
Sox30loxp/loxp mice group. Consistently, the testis
weight of Sox30loxp/loxp mice was indeed restoredwhen compared with that of Sox30/mice injected with solvent (Fig-
ure 5C; Figure S10). The histological results showed a presence of
spermatids and spermatozoa in many seminiferous tubules of testes
and a lot of spermatozoa in epididymides from fertile Sox30loxp/loxp
mice (Figure 6A). There were also spermatids and spermatozoa in
some seminiferous tubules of testes, but only a few spermatozoa in
epididymides from sterile Sox30loxp/loxp mice (Figure 6A).
To determine whether the recovery of spermatogenesis and fertility
is the result of Sox30 re-expression in Sox30 null mice, we evaluated
Sox30 expression in testes of these mice from the inducible system.
Sox30 expression was indeed restored in testes of Sox30loxp/loxp mice
(Figures 6B and 6C). These data indicate that the infertility of Sox30-
deﬁcient mice can be cured by re-expression of Sox30.
The Male Offspring of Sox30loxp/loxp Mice Can Still Father
Children
To determine the fertility of offspring after re-expression of Sox30 in
Sox30 null mice, we performed the fertility analyses of the male
offspring. In the offspring of the 6 fertile Sox30loxp/loxp mice, 12
were male mice, and each male mouse at 2 months was mated with
2 females with known fertility for a minimum of 20 weeks. These
male offspring were fertile in 91.67% (11/12). Moreover, the male
offspring of the fertile Sox30loxp/loxp mice and their children can
develop normally and live more than 1 year without signiﬁcant differ-
ence of physical appearance compared with wild-type mice. These
data show that the male offspring of Sox30loxp/loxp mice can still father
children normally.
DISCUSSION
More than 80% of NOA patients are unexplained, resulting in lack of
adequate clinical treatments. Although plenty of studies have tendedherapy: Nucleic Acids Vol. 19 March 2020 77
Figure 5. Infertility of Sox30–/– Mice Can Be Restored
by Sox30 Re-expression
(A) H&E staining of testes and epididymides from Sox30+/+,
Sox30/, and Sox30 re-expressed Sox30/ (Sox30loxp/loxp)
mice were shown. Spermatozoa and spermatids were
observed in testes and epididymides of Sox30loxp/loxp mice,
which were killed at 2 (n = 5) or 6 months (n = 5) after tam
injection. The arrows with long tail indicate spermatozoa in
testes and epididymides, and the arrows with short tail indi-
cate spermatids in testes. Scale bars, 50 mm. (B) The ability to
conceive of the re-presented spermatozoa was evaluated by
fertility analysis after re-expression of Sox30 in Sox30/
mice. (C) The weight of testes was analyzed in Sox30+/+
(n = 5), Sox30/ (n = 8), and Sox30loxp/loxp (n = 14) mice. +/+,
Sox30+/+mice injectedwith tam;/+, Sox30/+mice injected
with tam; /, Sox30/ mice injected with solvent;
loxp/loxp, Sox30/ mice injected with tam. ***p < 0.001;
**p < 0.01.
Molecular Therapy: Nucleic Acidsto explain the etiology of NOA by screening for genetic abnormality,
it is still elusive. DNA methylation as an epigenetic mechanism plays
key roles in various diseases.10–14 During spermatogenesis, the
genome of germ cells generally undergoes extensive DNA demethyla-
tion followed by DNA methylation.22 The abnormality of this prog-
ress is closely associated with male infertility.15–18 In the present
study, SOX30 was demonstrated to be a preferential hyper-methyl-
ation gene at promoter, and this hyper-methylation of SOX30 resulted
in its silence in NOA patients. The reduced levels of SOX30 expres-
sion are associated with the severity of NOA disease. Moreover, the
pathology and testicular volume of Sox30-deﬁcient mice simulate
those of NOA patients. These results indicate that SOX30 silenced
by hyper-methylation is likely an important contributor to the path-
ogenesis of NOA disease. In the morphological comparison between
testis tissues of Sox30-deﬁcient mice and NOA patients, maybe a
question will be raised that there are no multinucleated cells in the
phenotype images of NOA. It is likely that the silence of SOX30 in
these NOA patients is too long because the multinucleated cells
have also almost disappeared in testes of over 6-month-old Sox30-
deﬁcient mice. Further analysis of the phenotype of younger NOA
patients will be required to determine this issue in the future. In addi-
tion, our study reveals that SOX30 level is negatively associated with
NOA severity. This phenomenon may be related to the silent degree
of SOX30 caused by different hyper-methylation CpG sites and/or the
composition of different cell types (for example, the absence of sper-
matids) for NOA samples.
To determine whether the infertility of Sox30 deﬁciency can be
cured by re-expression of Sox30, we restored Sox30 expression in
Sox30/ adult mice by inductive deletion of ﬂoxed cassette and
evaluated the actual fertility of these Sox30loxp/loxp mice. The arrest
of spermatogenesis in Sox30/ mice can be restored after Sox30 re-
expression. Moreover, the re-presented spermatozoa seem to be
fertile, and their male offspring can also father children normally.78 Molecular Therapy: Nucleic Acids Vol. 19 March 2020These experimental data reveal that the infertility of Sox30
deletion can be successfully cured by restoration of Sox30 expression
in adult mice. Given that DNA methylation is reversible, SOX30
may be used to develop an important therapy for NOA
disease. The latest technologies developed for targeted DNA methyl-
ation editing23–25 will be useful for developing this therapy.
This work will be our focus for future study, which is now
underway.
In very recent works, Sox30 also has been found to be essential for
spermiogenesis,26–28 which further highlights the key role of
SOX30 in NOA diseases. Feng et al.26 and Zhang et al.27 reveal
that germ cells arrest at the post-meiotic round spermatids in
Sox30 knockout mice, and Bai et al.28 indicate that there is also
an accumulation of diplotene spermatocytes, suggesting a delayed
or impaired transition from meiosis to post-meiosis in Sox30
knockout mice. In our present study, we found few spermatids
and complete absence of spermatozoa in testes of Sox30 null
mice at 6 months. However, complete absence of spermatids and
spermatozoa was found in testes of Sox30 null mice at 8 months.
These data suggest that the male germ cells in Sox30 null mice may
mainly arrest at an earlier stage rather than post-meiotic round
spermatids. Although data of our study show that the number of
spermatocytes is drastically reduced in Sox30 null mice as they
aged, it seems that spermatocytes still exist in the old Sox30 null
mice. This phenomenon means that the male germ cells in
Sox30 null mice may arrest at an early stage of spermatocyte or
arrest in differentiation from spermatogonia to spermatocyte stage.
However, whether the germ cells in Sox30 null mice arrest at
spermatocytes or in differentiation from spermatogonia to sper-
matocyte is still unclear at the moment. Further research is
required to clarify the precise period of these germ cells arrest in
Sox30 null mice. In addition, the phenotype observed in our study
is somewhat different from that observed in previous studies,26–28
Figure 6. The Pathological Morphology of Mice Testes with Different Genotypes Was Shown
(A) H&E staining of testes and epididymides from Sox30+/+, Sox30/, and Sox30 re-expressed Sox30/ (Sox30loxp/loxp) mice was shown. Lots of spermatids were
observed in testes and epididymides of Sox30+/+ mice (n = 5) injected with tam, but were not observed in testes and epididymides of Sox30/ (n = 8) mice injected with
solvent. Many spermatids were observed in testes and epididymides of fertile Sox30loxp/loxp mice (n = 6). A considerable amount of spermatids was still observed in testes of
sterile Sox30loxp/loxp mice (n = 8), but only a few spermatids were found in epididymides of these mice. The arrows in epididymides represent spermatozoa; the arrows in
testes represent spermatozoa and spermatids. Scale bars, 100 mm. (B and C) qRT-PCR (B) andWB (C) analyses of the expression of Sox30 in testes of Sox30+/+, Sox30/,
and Sox30loxp/loxp mice were performed. ***p < 0.001. b-Actin was used as an internal control.
www.moleculartherapy.orgwhich may be caused by different strategies to create Sox30-deﬁ-
cient mice (for example, systemic and conditional knockout) or
by differences in the degree of gene knockout. Anyway, the data
of the recent reports and our present study show that Sox30 is a
key participant in male infertility, which further strengthens the
important contributor of inactive SOX30 to human NOA disease.
The most interesting result of our present study is that the pheno-
type and fertility can be reversed by restoration of Sox30 using an
inducible knockout model. The presence of many spermatozoa is
observed, and the actual fertility is restored following inducible
Sox30 expression in adult Sox30/ mice. However, it appears
that despite analyses of several complete cycles of spermatogenesis
(over 8 months), there is still a marked difference of the phenotype
and fertility between Sox30+/+ and Sox30loxp/loxp mice. The possible
cause may be the incomplete restoration of Sox30 in Sox30loxp/loxp
mice due to efﬁciency of recombination. The expression analyses
demonstrate that the expression of Sox30 is indeed incompletelyrestored in testes of Sox30loxp/loxp mice compared with Sox30+/+
mice.
A remaining question of this study is whether the effect of Sox30 on
male germ cells is cell autonomous or non-cell autonomous. To
clarify this issue, two experiments should be performed in the future:
(1) different conditional knockout mouse lines (only germ cell
knockout of Sox30 and only Sertoli cell knockout of Sox30) will be
generated to compare the different effect of Sox30 on male germ cells;
and (2) the spermatogonia of Sox30+/+ mice will be transplanted to
testes of Sox30/ mice to observe the changes of spermatogenesis.
In summary, our study ﬁnds that methylated inactivation of SOX30
speciﬁcally impairs testis development and spermatogenesis prob-
ably causing NOA disease (Figure 7), and re-expression of SOX30
can successfully restore the spermatogenesis and actual fertility.
This study provides an important therapy target for human NOA
disease.Molecular Therapy: Nucleic Acids Vol. 19 March 2020 79
Figure 7. A Schematic Illustration of Human NOA Disease Development by
SOX30
In post-natal testes, when the promoter is un-methylated, SOX30 is highly ex-
pressed and the spermatogenesis is normal. However, when the promoter is hyper-
methylated, SOX30 expression is silenced. The spermatogenesis is arrested, and
the NOA disease is developed.
Molecular Therapy: Nucleic AcidsMATERIALS AND METHODS
Patients
Testicular biopsy specimens were obtained from OA and NOA pa-
tients at Daping Hospital. The patients with previous testicular injury
were excluded. Clinical assessment of infertile men was done as
described previously.29 These infertile male patients have received a
routine semen examination according to theWorld Health Organiza-
tion (WHO) criteria. Azoospermia was conﬁrmed for all men on two
different occasions by testing centrifuged ejaculates according to
WHO guidelines.30 The patients were ﬁrst diagnosed as azoospermia
due to no ejaculated spermatozoa in semen. Then, OA was deﬁned
based on the following characteristics: no sperm in the semen, visible
sperm in testicular tissue or motile spermatozoa sampled fromMESE,
or number of mature spermatozoa sampled using TESE, normal
testicular volume, normal blood hormone, and normal semen
biochemistry. The 15 OA men aged 20–42 years who exhibit normal
tissue morphology with a large number of sperm and no signiﬁcant
reduction of all type spermatogenic cells in testes were selected as con-
trol tissues from 326 OA patients (the ideal normal tissue control is
the volunteer with known fertility, but the difﬁculties in acquiring
testicular samples of the volunteers make this strategy impractical).
These patients were identiﬁed as the NOA men according to the
following characteristics: no sperm in semen, small testicular volume,
abnormal blood hormone and semen biochemistry, no sperm in
testicular tissue, and/or a reduction of spermatogenic cells in testic-
ular tissue. The NOA samples were divided into different groups
based on the clear composition of cell types and pathological
morphology, and ﬁnally, 58 NOAmen aged 20–45 years were selected
from 176 NOA patients, including 31 cases of NOA patients without
spermatozoa (NOA-I), 22 cases of NOA patients without spermatid
(NOA-II), and 5 cases of NOA patients without spermatocyte80 Molecular Therapy: Nucleic Acids Vol. 19 March 2020(NOA-III), for further study. In these NOA patients, the clinical ge-
netic testing including Y chromosome microdeletion and karyotype
was performed in 84.48% (49/58) cases, and no positive ﬁndings of
genetic test were observed. When deﬁning OA, NOA-I, NOA-II,
and NOA-III, we examined multiple sections from at least three sepa-
rate parts of the testicular tissue sample to determine these qualiﬁca-
tions by two independent pathologists. In the 15 OA patients and 58
NOA patients, 5 OA patients underwent MESE, 10 OA patients un-
derwent TESE, and 7 NOA men underwent microsurgical TESE
(microTESE) for assisted reproduction. These 15 OA patients selected
who underwent TESE or MESE can father children by assisted repro-
ductive technology. None of these patients were exposed to adjuvant
hormonal therapy, chemotherapy, and radiation prior to biopsy. The
following parameters were recorded for each patient: a detailed med-
ical history, physical examination including the presence or absence
of a varicocele, and a hormone proﬁle. Testicular volume using a stan-
dard orchidometer was noted. Hormonal evaluation included serum
follicle-stimulating hormone (FSH), luteinizing hormone (LH), and
total testosterone (TT). There was no family history for the male ste-
rility of all the patients. This study was approved by the ethics com-
mittees of Daping Hospital Afﬁliated to Army Medical University,
and informed consent was signed by all of the patients. All experi-
ments were carried out in accordance with the approved guidelines
of Army Medical University.
DNA Extraction and Construction of Whole Genome Bisulfite
Sequencing Libraries
The genomic DNA was extracted using the MagPure FFPE DNA LQ
Kit (Magen) according to the manufacturer’s instructions. The ﬁxed
samples from ﬁve OA or ﬁve NOA patients who underwent testicular
puncture between 2015 and 2016 (stored at 4C) were pooled together
for extraction. No signiﬁcant DNA degradation was found for the ex-
tracted genomic DNA determined by 1% agarose gel electrophoresis.
The concentration and integrity of genomic DNA were analyzed on a
Qubit ﬂuorometer using a Quant-iT dsDNA HS Assay kit (Invitro-
gen) and the Bioanalyzer analysis system (Agilent), respectively.
The libraries were constructed using the Fragmented MicroMethyl
DNA library kit (E-GENE) according to the manufacturer’s instruc-
tions. In brief, the genomic DNA was further fragmented by an ultra-
sonic instrument followed by end-repairing and dA addition to the
30 end using end repair enzymes. After the reaction, methylation-
modiﬁed adaptor was ligated to the genomic DNA. The adaptor
ligated DNA was further treated with bisulﬁte conversion, followed
by PCR ampliﬁcation. The products were puriﬁed using 0.8-fold dilu-
tion puriﬁcation beads and then quantiﬁed using the Bioanalyzer
analysis system (Agilent) and real-time PCR assay. The qualiﬁed
libraries were ﬁnally analyzed using an Illumina HiSeq.
Bisulfite-Sequencing Read Processing and Alignment
After sequencing, adapters were removed using cutadapt-1.2.1 soft-
ware (https://cutadapt.readthedocs.io/en/stable/), and only reads
with minimally 45-bp length were kept. After removing the adapters,
low-quality reads that containedmore than 10%Ns ormore than 50%
of the sequence with low-quality value (quality value <5) per read
www.moleculartherapy.orgwere ﬁltered out. Reads mapping was done using BSMAP (version
2.73) alignment software that combines genome hashing and bitwise
masking to achieve fast and accurate bisulﬁte mapping, allowing for
maximally ﬁve mismatches or one small insertion or deletion. After
mapping, PCR duplicates were removed using SAMtools software.
Finally, methylation level of each cytosine in human genome was
calculated on the basis of the alignments by using a Python script
metyratio.py supplied with BSMAP.
Global Patterns of DNA Methylome
Circos (version 0.67) was used to visualize the global pattern of DNA
methylome. The G (Guanine) and C (Cytidine) (GC) content, repeat
sequence ratio, gene sequence proportion, and average methylation
level of each 500-kb window on the whole genome were calculated.
Chromosome name and scale are indicated on the outer rim.
Identification of DMR
The software metilene (version [v.]0.2-6) was used to screen regions
in the genome that were differentially methylated between OA and
NOA samples. Metilene uses a circular binary segmentation and a
two-dimensional Kolmogorov-Smirnov (2D-KS) test to call DMRs.
Adjusted p values are calculated using the Bonferroni correction.
Only cytosine sites covered by at least ﬁve reads were used. Regions
containing CpG sites R10, adjusted p values <0.01, q values <0.05,
and changes of methylation level between two samples >0.2 were
identiﬁed as DMRs.
Identification and Annotation of Sequence Variation with
Bisulfite-Sequencing Data
BS-SNPer that can identify mono-allelic DNA methylation and poly-
morphisms in cis-regulatory sequences was used to detect SNPs in our
DNA bisulﬁte treatment sequencing data. First, SNPs were identiﬁed
in each sample according to the following ﬁltering criteria: (1) a SNP
had to be covered by at least 10 reads; (2) the minimum base quality
for calling a base was 15; (3) the minimum phred-scaled conﬁdence
threshold at each variant for calling should be 20; (4) the minimum
heterozygous frequency should be >0.1; and (5) the minimum homo-
zygous frequency should be >0.85. After detection of SNPs, annovar
(2017-07-17) was used to functionally annotate genetic variants de-
tected from human genomes (hg19) and identify whether SNPs cause
protein-coding changes and the amino acids that are affected.
DNA Isolation, Preparation, andMethylationMicroarrayAnalysis
DNA isolation, preparation, andmethylationmicroarray analysis were
performed in three OA and three NOA independent patient samples
(the cell types and pathological morphology of these three OA and
three NOA men were very similar to the original cohort of ﬁve OA
and ﬁve NOA men, respectively: one of three OA patients/two of
ﬁve OA in the original cohort were slightly reduced in spermatogenic
cells with many sperm in testis tissues, and two of three OA patients/
three of ﬁveOA in the original cohort were not signiﬁcantly reduced in
all type spermatogenic cells with a lot of sperm in testis tissues; two of
three NOA patients/three of ﬁve NOA in the original cohort were
highly similar to the NOA-III patients without spermatocyte, andone of three NOA patients/two of ﬁve NOA in the original cohort
were highly similar to the NOA-II patients without spermatids). These
three OA and three NOA men were also used for the following RNA
extraction and gene expression microarray as previously described.19
In brief, the frozen testicular tissue was dissolved in lysis buffer and
Proteinase K from DNA Micro Kit (QIAGEN, Germany). Genomic
DNA was extracted using a DNA Micro Kit based on the manufac-
turer’s instructions (QIAamp DNA Micro Kit; QIAGEN). For each
sample, bisulﬁte modiﬁcation of DNA (500 ng) was performed using
the EZ DNA methylation kit (Zymo Research, Orange, CA, USA)
based on the manufacturer’s instructions. After bisulﬁte conversion,
bisulﬁte-converted DNA (4 mL) was used to hybridize on the array
(Inﬁnium Human Methylation 450 BeadChips; Illumina). Bead-
bound probes were used to quantify the amount of thymine or
cytosine in the hybridization process. Fluorescent signal of two bead
types was obtained using BeadArray Reader. Methylation status of
the CpG sites was calculated with average beta value. The beta value
was the ratio of the signal intensity for the methylated probe to the
sum for methylated and unmethylated probes.
RNA Extraction and Gene Expression Microarray
RNA extraction and gene expression microarray were performed in
the three OA and three NOA patient samples as previously
described.19 In brief, total RNAs were extracted from the frozen testic-
ular tissues using miRNeasy Micro Kit (QIAGEN, Germany). An Agi-
lent 2100 Bioanalyzer and RNA 6000 NanoLabChip Kit (Agilent
Technologies, Waldbronn, Germany) were used to determine the
RNA concentration and integrity, respectively. Total RNAs (100 ng)
were prepared with Agilent’s Labeling kit (One-Color Microarray-
Based Gene Expression Analysis Low Input Quick Amp Labeling
kit) for microarray hybridization and were then hybridized to Agilent
SurePrint G3 human gene expression microarray based on the manu-
facturer’s instructions. The Agilent microarray scanner (G2565CA)
was used to scan the arrays. The data of themicroarray were processed
using Agilent Feature Extraction 10.7.3.1 Software (Agilent).
Immunohistochemical Analysis
IHC was performed using SOX30 antibody (1:50; ab26024; Abcam,
Cambridge, MA, USA) as described previously.21 After IHC staining,
we consolidated the results by positive percentage and intensity of
staining using a scoring system. Positive percentage of staining was
classiﬁed into ﬁve categories: <5% positive cells for 0 score, 5%–
25% for 1 score, 26%–50% for 2 score, 51%–75% for 3 score, and
R76% for 4 score. Intensity of staining was graded into three groups:
negative scored as 0, weak staining scored as 1, moderate staining
scored as 2, or strong staining scored as 3. Expression levels of
SOX30 in samples were deﬁned by the sum of category for positive
percentage and grade for intensity of staining, and the range of the
calculation was 0–7. All samples were independently reviewed by
two blinded pathologists.
Sox30 Null Mice
Sox30 null mice were generated by Model Animal Research Center of
Nanjing University. In brief, a targeted gene including homologousMolecular Therapy: Nucleic Acids Vol. 19 March 2020 81
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GFP-NEO-STOP-PPS-LoxP cassette was introduced between
Exon1 and Exon2 of Sox30 by homologous recombination. The tar-
geting vector was conﬁrmed by PCR, enzyme digestion, sequencing,
and then linearized with AsiSI and electroporated into C57BL/6 em-
bryonic stem cells (ESCs). The recombinants were selected by G418
and ganciclovir (Ganc); then the targeted ESCs were screened by
PCR and Southern blotting. Finally, the positive clones were chosen
for microinjection to generate the chimeras, which were crossed
with C57BL/6 mice to produce the heterozygous mice. To restore
Sox30 expression, we generated mice expressing Cre recombinase
by breeding Sox30 heterozygous (Sox30+/) mice with B6.Cg-trans-
genic (Tg) (CAG-cre/Esr1)5Amc/JNju tool mice (stock no. 004682;
The Jackson Laboratory), to produce Sox30-KI (knockin) and Cre
double-positive heterozygote mice. Tam-inducible Cre-mediated
recombination will result in deletion of the ﬂoxed sequences in the
offspring of these mice. The genotype of the offspring was identiﬁed
by PCR. Mice were maintained in a speciﬁc pathogen-free unit under
a 12-h light, 12-h dark cycle with ad libitum access to water and food.
All mouse experiments were carried out with the permission of Insti-
tutional Animal Care and Use Committee of Nanjing University and
Army Medical University, China.
Fertility Assays
Breeding assays with wild-type (Sox30+/+), heterozygous (Sox30+/),
and homozygous (Sox30/) mice were carried out. At least 30 inde-
pendent mice (8–10 weeks old) of each sex for different genotypes
were mated with known fertility wild-type mice for a minimum of
8 weeks. If progeny were born, the line was classed as fertile.
Epididymal Sperm Count by Sperm Class Analyzer
The epididymis was dissected from adult mice and cut into pieces in
0.5 mL of medium incubating for 10 min at 37C. Each sample
(10 mL) was transferred to a Glodcyto standard count chamber slide
(Microptic, Barcelona, Spain), warmed on amicroscope heating stage.
Sperms on the slides were observed and counted at least in ﬁve
random ﬁelds by Sperm Class Analyzer (SCA) system (Microptic,
Barcelona, Spain).
RNA and Protein Extraction
Total RNA of testis tissues was extracted using TRIzol Reagent (Invi-
trogen) and treated with DNase I to eliminate the genomic DNA
contamination. cDNA was synthesized using GoScript Reverse Tran-
scription System (Promega) and stored at 20C. The protein of
testis tissues was extracted using lysis buffer (Beyotime, Shanghai,
China) containing complete protease inhibitor (Roche, Mannheim,
Germany) and stored at 80C after centrifugation.
qRT-PCR
qRT-PCR was performed using CFX96 Real-Time PCR Detection
System (Bio-Rad Laboratories) and GoTaq qPCR Master Mix
(Promega, USA) as previously described.31 The expression was calcu-
lated by 2DDCT. All assays were performed in triplicate three times.
The primers used in this study were listed in Table S1.82 Molecular Therapy: Nucleic Acids Vol. 19 March 2020Restoration of Sox30 Expression in Sox30–/– Mice by Tam
Injection
To induce Cre-mediated Sox30 expression, we injected tam (Sigma-
Aldrich, St Louis, MO, USA) into mice once a day intraperitoneally
(i.p.) for 5 days with 1 mg/mouse to remove the insertion cassette
via activating the Cre recombinase (the control Sox30/ mice were
injected with solvent i.p following the same steps). The mice were in-
jected with tam or solvent at 2 months old and were sacriﬁced at 2 or
6 months after the ﬁrst injection. The histology of testes was exam-
ined by microscopy.
Fertility Analysis for Recovery Mice
Breeding assays were performed in Sox30+/+ male mice injected with
tam, Sox30/+ male mice injected with tam, Sox30/ male mice in-
jected with tam (Sox30loxp/loxp), and the control Sox30/ male
mice injected with solvent. Each male mouse (2 months old when
injected with tam or solvent) at 6 months after tam injection was
mated with two known fertility wild-type females for a minimum
of 20 weeks. If progeny were born, the treated male mouse was
deﬁned as fertile.
Histology H&E Staining
Testes were dissected and immediately ﬁxed in Bouin’s ﬂuid. The
ﬁxed testes were dehydrated, embedded in parafﬁn, and cut into
5-mm-thick sections. These sections were de-waxed, rehydrated,
and stained with H&E.
Transmission Electron and Optical Microscopy
Testes were dissected, cut into 1-mm cubes, and placed into fresh
2.5% (w/v) glutaraldehyde overnight at 4C. The tissues were washed
in PBS post-ﬁxed for 1 h in 1% osmium tetroxide at room tempera-
ture, dehydrated through a graded series of ethanol and acetone,
and inﬁltrated with and embedded in Epon 812. Sections (100 nm)
were obtained with an ultramicrotome, stained with uranyl acetate
and lead citrate, and observed under JEM-1400 Plus transmission
electron microscope (JEOL, Japan). Semi-thin sections (1 mm) were
stained with toluidine blue and examined by optical microscope
(Olympus, Japan).
Western Blotting Analysis
Western blotting (WB) analysis was performed as previously
described.31 The SOX30 rabbit polyclonal antibody (1:1000,
ab26024; Abcam) was used. The secondary (anti-rabbit) antibody
was horseradish peroxidase (HRP)-conjugated.
Statistical Analysis
Statistical analyses were performed using SPSS 15.0 software (SPSS,
Chicago, IL, USA). The data were expressed as mean ± SEM. The dif-
ferences between two or three groups were analyzed using Student’s t
test, Tukey’s test, and one-way ANOVA. The different methylations
between OA and NOA patients who underwent global DNA methyl-
ation were analyzed using 2D KS test and Mann-Whitney U (MWU)
test. The p values less than 0.05 were considered statistically
signiﬁcant.
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